235 related articles for article (PubMed ID: 26459098)
21. CHK1 and CHK2 are differentially involved in mismatch repair-mediated 6-thioguanine-induced cell cycle checkpoint responses.
Yan T; Desai AB; Jacobberger JW; Sramkoski RM; Loh T; Kinsella TJ
Mol Cancer Ther; 2004 Sep; 3(9):1147-57. PubMed ID: 15367709
[TBL] [Abstract][Full Text] [Related]
22. Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer.
Abdel-Fatah TM; Middleton FK; Arora A; Agarwal D; Chen T; Moseley PM; Perry C; Doherty R; Chan S; Green AR; Rakha E; Ball G; Ellis IO; Curtin NJ; Madhusudan S
Mol Oncol; 2015 Mar; 9(3):569-85. PubMed ID: 25468710
[TBL] [Abstract][Full Text] [Related]
23. Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression.
Di Benedetto A; Ercolani C; Mottolese M; Sperati F; Pizzuti L; Vici P; Terrenato I; Shaaban AM; Humphries MP; Di Lauro L; Barba M; Vitale I; Ciliberto G; Speirs V; De Maria R; Maugeri-Saccà M
Sci Rep; 2017 Aug; 7(1):8078. PubMed ID: 28808232
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of CHK1 activation in vulvar squamous cell carcinoma and its potential as a therapeutic target in vitro.
Wang Z; Førsund MS; Trope CG; Nesland JM; Holm R; Slipicevic A
Cancer Med; 2018 Aug; 7(8):3955-3964. PubMed ID: 29963769
[TBL] [Abstract][Full Text] [Related]
25. The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells.
Wang FZ; Fei HR; Cui YJ; Sun YK; Li ZM; Wang XY; Yang XY; Zhang JG; Sun BL
Apoptosis; 2014 Sep; 19(9):1389-98. PubMed ID: 24928205
[TBL] [Abstract][Full Text] [Related]
26. Mitotic DNA damage response: Polo-like kinase-1 is dephosphorylated through ATM-Chk1 pathway.
Lee HJ; Hwang HI; Jang YJ
Cell Cycle; 2010 Jun; 9(12):2389-98. PubMed ID: 20581453
[TBL] [Abstract][Full Text] [Related]
27. mTORC1 and DNA-PKcs as novel molecular determinants of sensitivity to Chk1 inhibition.
Massey AJ; Stephens P; Rawlinson R; McGurk L; Plummer R; Curtin NJ
Mol Oncol; 2016 Jan; 10(1):101-12. PubMed ID: 26471831
[TBL] [Abstract][Full Text] [Related]
28. Role of Chk1 and Chk2 in Ara-C-induced differentiation of human leukemia K562 cells.
Takagaki K; Katsuma S; Kaminishi Y; Horio T; Tanaka T; Ohgi T; Yano J
Genes Cells; 2005 Feb; 10(2):97-106. PubMed ID: 15676021
[TBL] [Abstract][Full Text] [Related]
29. Targeting radioresistant breast cancer cells by single agent CHK1 inhibitor via enhancing replication stress.
Zhang Y; Lai J; Du Z; Gao J; Yang S; Gorityala S; Xiong X; Deng O; Ma Z; Yan C; Susana G; Xu Y; Zhang J
Oncotarget; 2016 Jun; 7(23):34688-702. PubMed ID: 27167194
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage.
Syljuåsen RG; Sørensen CS; Hansen LT; Fugger K; Lundin C; Johansson F; Helleday T; Sehested M; Lukas J; Bartek J
Mol Cell Biol; 2005 May; 25(9):3553-62. PubMed ID: 15831461
[TBL] [Abstract][Full Text] [Related]
31. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.
Smith J; Tho LM; Xu N; Gillespie DA
Adv Cancer Res; 2010; 108():73-112. PubMed ID: 21034966
[TBL] [Abstract][Full Text] [Related]
32. Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy.
Al-Subhi N; Ali R; Abdel-Fatah T; Moseley PM; Chan SYT; Green AR; Ellis IO; Rakha EA; Madhusudan S
Breast Cancer Res Treat; 2018 Jun; 169(2):277-286. PubMed ID: 29396668
[TBL] [Abstract][Full Text] [Related]
33. DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system.
Caporali S; Falcinelli S; Starace G; Russo MT; Bonmassar E; Jiricny J; D'Atri S
Mol Pharmacol; 2004 Sep; 66(3):478-91. PubMed ID: 15322239
[TBL] [Abstract][Full Text] [Related]
34. DNA protein kinase-dependent G2 checkpoint revealed following knockdown of ataxia-telangiectasia mutated in human mammary epithelial cells.
Arlander SJ; Greene BT; Innes CL; Paules RS
Cancer Res; 2008 Jan; 68(1):89-97. PubMed ID: 18172300
[TBL] [Abstract][Full Text] [Related]
35. Chk1- and claspin-dependent but ATR/ATM- and Rad17-independent DNA replication checkpoint response in HeLa cells.
Rodríguez-Bravo V; Guaita-Esteruelas S; Florensa R; Bachs O; Agell N
Cancer Res; 2006 Sep; 66(17):8672-9. PubMed ID: 16951182
[TBL] [Abstract][Full Text] [Related]
36. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.
Prevo R; Fokas E; Reaper PM; Charlton PA; Pollard JR; McKenna WG; Muschel RJ; Brunner TB
Cancer Biol Ther; 2012 Sep; 13(11):1072-81. PubMed ID: 22825331
[TBL] [Abstract][Full Text] [Related]
37. Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma.
Baranski Z; Booij TH; Cleton-Jansen AM; Price LS; van de Water B; Bovée JV; Hogendoorn PC; Danen EH
J Pathol; 2015 Jul; 236(3):348-59. PubMed ID: 25757065
[TBL] [Abstract][Full Text] [Related]
38. Development of pharmacodynamic biomarkers for ATR inhibitors.
Chen T; Middleton FK; Falcon S; Reaper PM; Pollard JR; Curtin NJ
Mol Oncol; 2015 Feb; 9(2):463-72. PubMed ID: 25459351
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer.
Alshareeda AT; Negm OH; Albarakati N; Green AR; Nolan C; Sultana R; Madhusudan S; Benhasouna A; Tighe P; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2013 Jun; 139(2):301-10. PubMed ID: 23624778
[TBL] [Abstract][Full Text] [Related]
40. Cdk inhibition in human cells compromises chk1 function and activates a DNA damage response.
Maude SL; Enders GH
Cancer Res; 2005 Feb; 65(3):780-6. PubMed ID: 15705874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
